Background: Long-term follow-up studies revealed a significant decline in the benefits of intracoronary radiation for in-stent restenosis.
ntracoronary brachytherapy with γ-and β-emitters has been shown to be effective in the treatment of in-stent restenosis in randomized clinical studies. [1] [2] [3] [4] Similarly, studies evaluating balloon-based systems using the liquid rhenium-188 ( 188 Re) isotope showed that this approach is feasible, safe, and effective in the prevention of repeat restenosis in cases of in-stent restenosis. 5-9 However, the benefits of intracoronary brachytherapy have been offset by late target vessel revascularization catch-up phenomenon and late stent thrombosis. 10- 18 We conducted this study to determine the 6-year clinical outcomes of β-radiation using a liquid 188 Re-filled balloon following cutting balloon angioplasty (CBA) for diffuse in-stent restenosis lesions (≥10 mm) in native coronary arteries. Because we performed most of our interventional procedures transradially, we selected this approach for intracoronary brachytherapy.
Methods
This study was approved by the Ethics Committee of our institution and the Ministry of Health. It was initially designed as a randomized prospective study in which 25 study patients HANG CL et al. and 25 control patients were enrolled. However, we could not randomize the patients because 188 Re isotope was produced only once every 1-2 weeks at the Institute of Nuclear Energy Research, Taiwan. Therefore, the assignment of patients to either the irradiation or control group depended on the availability of 188 Re. There was no attempt to match the control group with the irradiation group. The patients in our study comprised 25 study patients who received 14-Gray (Gy) irradiation to a tissue depth of 1 mm and 25 control patients who did not receive post-CBA irradiation. At the time of registration, the patients were evaluated by a radiation oncologist and an interventional cardiologist. After the risks and benefits were discussed with the patients, those who signed informed consent forms were enrolled either in the irradiation or the control group according to the availability of 188 Re. The patients were enrolled in the study if they met the following criteria: (1) 40 years of age or older; (2) should have undergone CBA for diffuse in-stent restenosis lesions (≥10 mm in length) in a native coronary artery; and (3) should have a target lesion with a reference vessel of ≥2.5 cm in diameter. Patients were excluded from the study if: (1) they exhibited a final angiographic residual stenosis of greater than 30% following on-line quantitative coronary analysis (QCA); (2) there was angiographic evidence of thrombus in the target lesion; (3) they were pre-menopausal; (4) they had previously received thoracic therapeutic irradiation; (5) they had advanced renal failure (serum creatinine concentrations greater than 3.0), left ventricular ejection fraction <25%, evolving myocardial infarction (MI) or within 72 h; (6) they had used thrombolytic or GpIIb/IIIa inhibitors within 48 h before the study; or (7) they had irradiation delivery failure. All patients were from Chang Gung Memorial Hospital, Kaohsiung, Taiwan. All the patients were maintained on 100 mg/day of aspirin indefinitely unless contraindicated. After the procedure, the irradiated study patients were administered 75 mg/day of clopidogrel in addition to aspirin for at least 6 months.
At 1 month, 6 months and within or at 6 years after the index procedure, information with regard to recurrent ischemic symptoms, death, non-fatal target vessel MI, and need for revascularization of the treated vessel was collected from patients' charts, outpatient visits or telephone contact with the patients. Approximately 6 months after the procedure, all patients were admitted to the hospital for repeat coronary angiography. All patients who received intracoronary brachytherapy and did not have restenosis at the 6-month angiographic follow-up were requested to undergo repeat coronary angiography around 3 years after the procedure.
Procedure
Radial arterial access was established by insertion of a 7-French (Fr) sheath in the 188 Re and control patients. A 7-Fr lumen guiding catheter was used to accommodate the size of the intravascular ultrasonography (IVUS) catheter (3.2-Fr Ultracross System; Boston Scientific Scimed, Maple Grove, MN, USA) in the 188 Re and control patients. The cutting balloon sizes were selected on the basis of visual estimation or QCA of the reference vessel diameters. The pressure or size of the cutting balloon was gradually increased in order to achieve a less than 35% residual stenosis by on-line QCA. After successful CBA, the media to media measurements at the index study were obtained by using IVUS in order to adjust the radiation dose. We obtained the media to media measurements of the vessel size at different sites of the target vessel, approximately 5 mm proximal and distal to the lesion and at the site of the lesion itself. The vessel size data, the length and nominal size of the perfusion balloon catheter and the activity of 188 Re were used to calculate the irradiation (dwell) times required to deliver 14 Gy of irradiation to a tissue depth of 1.0 mm; this corresponded to a dose of 52 Gy at the surface of the balloon. The computer treatment-planning program was provided by Columbia University, New York, NY, USA.
The IVUS study was used to determine only the vessel size but not the adequacy of CBA in the irradiation group. No further intervention was performed using IVUS for unsatisfactory post-CBA results such as small minimal luminal diameter (MLD). However, in the control group, an IVUS study was used to determine the adequacy of CBA. Irradiation and control procedures were carried out after successful CBA without additional stent deployment or the use of any other devices. A Lifestream perfusion balloon dilatation catheter (Advanced Cardiovascular Systems, Santa Clara, CA, USA) was used in the 188 Re group to deliver the irradiation. The size of the perfusion balloon for the delivery of the 188 Re isotope was within ±1.0 mm of that of the reference vessel diameter determined in the IVUS. The balloon was prepared by applying negative pressure via a 3-way valve using an empty 10-ml syringe. The 188 Re-filled leaded glass syringe was connected to the balloon via the 3-way valve, and the entire proximal balloon inflation structure was then embedded in a leaded acrylic shield. The irradiation extended at least 2 mm beyond the barotrauma site from the cutting balloon and a proximal and distal edge zone to avoid a geographic miss in the study group. A small amount of 188 Re solution (without contrast) was injected into the empty 10-ml syringe on the end of the 3-way valve in order to eliminate the small amounts of air present in the system. The perfusion balloon containing the 188 Re solution was manually inflated at an inflation pressure of approximately 3 atm. Cineangiograms were obtained using contrast injections to verify the position and full expansion of the balloon.
Quantitative Coronary Angiography
Angiographic measurements were performed using the online QCA image system. Image calibration was performed using a contrast-filled catheter. The external diameter of the catheter was used as the calibration standard. Coronary MLD and the degree of diameter stenosis were measured from coronary end-diastolic matched frames in the single worst view that was obtained before dilatation at the end of the procedure and during a follow-up angiography.
Definitions
Major adverse cardiac events (MACE) included the following events: cardiac death, non-fatal MI, total reocclusion without revascularization and target lesion revascularization (TLR). MI was defined as an elevation of the MB fraction of creatine kinase to a value 3 times the upper limit of the normal range. Geographic miss was defined as a case in which a segment of the target vessel was injured or in contact with the cutting balloon received a low radiation dosage because radiation did not completely cover this area. Restenosis was defined as the presence of stenosis of more than 50% of the luminal diameter. TLR was defined as the re-intervention to treat the injured segment of the target lesion (including 5 mm beyond the approximate proximal and distal locations of the previous angioplasty balloon or stent) resulting from stenosis of ≥50% of the diameter. Composite clinical endpoints were defined as cardiac and non-cardiac death, non-fatal MI, total re-occlusion without revascularization and TLR.
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Statistical Analysis
Statistical analyses of frequency counts were performed with the use of the chi-squared test or Fisher's exact test for small samples. Differences between the 2 groups were examined by 2-tailed Student's t-test. All tests were 2-sided. Values were reported as means ± SD. A P-value of less than 0.05 was considered to be significant.
Results
The 2 groups had similar baseline clinical and pre-procedure angiographic characteristics except the pre-procedure reference diameter, which was significantly higher in the irradiated group (irradiated vs. control; 3.1±0.5 mm vs. 2.8±0.5 mm; P= 0.039) (Tables 1-3 ). The 2 groups had similar post-procedure reference diameter (irradiated vs. control; 3.1±0.5 mm vs. 3.2± 0.5 mm; P=0.48) ( Table 3 ). The post-procedure MLD in the control group was significantly larger than that in the irradiated group (irradiated vs. control; 2.4±0.6 vs. 2.8±0.5; P= 0.014) ( Table 3 ). The post-procedure percent of stenosis in the control group was significantly lesser than that in the irradiated group (irradiated vs. control; 22±12% vs. 14±10%; P=0.014) ( Table 3 ). The average specific activity of the 188 Re was 140±66 mCi/ml (range, 68-256 mCi/ml). The mean dwell time was 763±307 s. The treatment was administered in a single inflation cycle in all but 4 patients, in whom stepping procedure was performed for a long irradiated length. No HANG CL et al.
death, non-fatal MI, or revascularization was noted at the 30-day follow-up. Angiographic follow-up data were obtained at 6 months in all the patients in the control and the irradiated groups ( Table 4 ). Angiographic restenosis either within the lesion or at its edge was observed in 16% (4 of the 25 patients) of the patients in the irradiated group and 48% (12 of the 25 patients) of the patients in the control group (P=0.03). Six-month clinical follow-up data were obtained for all patients ( Table 5) . No MI or death was observed in these patients. Three of the 4 irradiated and 10 of the 12 control patients who had angiographic restenosis experienced recurrent angina around 6 months after the procedure. One patient in the irradiated and 1 in the control group exhibited silent total occlusion of the target vessel underwent bypass surgery and received medical treatment respectively. Repeat percutaneous transluminal coronary angioplasty (PTCA) was performed in 2 of 25 (8%) patients with restenosis in the irradiated group and in 8 of the 25 (32%) patients in the control group (P=0.07). One patient in the irradiated group and 1 in the control group who had total occlusion of the target lesion underwent bypass surgery. TLR was performed in 3 of 25 (12%) patients with reste- Intracoronary-Irradiation With Liquid Rhenium-188 Figure. (A) Six-year survival free from target lesion revascularization (TLR) (Kaplan -Meier) for the irradiated and control patients. Curves diverged at 6 months, after which events were infrequent. Intracoronary brachytherapy improved freedom from TLR from 60% to 84% (P=0.058). (B) Six-year survival free from major adverse cardiac events (MACE) (Kaplan -Meier) for the irradiated and control patients. MACE was defined as cardiac death, non-fatal myocardial infarction, total re-occlusion without revascularization and TLR. Curves diverged at 6 months, after which clinical events were infrequent. Intracoronary brachytherapy significantly improved freedom from MACE from 52% to 80% (P=0.032).
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nosis in the irradiated group and 9 of the 25 (36%) patients in the control group (P=0.095). MACE rates were significantly different between the irradiated and control group (3/25 (12%) vs. 11/25 (44%); P=0.025). Long term (6 months -6 years) angiographic follow-up data were obtained for 4 of 13 (31%) control patients and 16 of 21 (76%) irradiated patients who did not have restenosis at 6 months of follow-up (Tables 6). Angiographic restenosis either within the lesion or at its edge were observed in 6% (1 of 16) of the patients in the irradiated group and 50% (2 of 4) of the patients in the control groups (P = NS). Focal in-stent restenosis occurred in 1 irradiated patient. In the control group, 1 had diffuse in-stent restenosis and 1 had diffuse proliferative restenosis. None of the patients in either group exhibited late total occlusion.
Long term clinical follow-up data were obtained for all patients ( Table 7) . The mean follow-up durations were 64.9± 13.0 and 66.3±13.8 months for the irradiated and control groups, respectively. No new bypass surgery was further performed in either group. One irradiated patient who had no restenosis at 6 months, developed recurrent angina and underwent a repeat stent implantation for the restenosis of the target lesion 30 months after the procedure. One of the non-restenosis patients in the irradiated group had a stroke 8 months after the procedure and died of pneumonia 4 months later. One irradiated patient received medical treatment for restenosis at 6 months and died of lung carcinoma 48 months after the index procedure. One uncomplicated non-target vessel MI occurred in the irradiated group. For those control patients who exhibited no restenosis at 6 months but had recurrent angina, 1 received medical treatment for 50% diffuse in-stent restenosis of the target lesion and the other 2 underwent repeat stent implantation for diffuse proliferative restenosis of the target lesion 15 and 72 months after the index procedure, respectively. One control patient who underwent PTCA for restenosis at 6 months developed unstable angina 3 years after the last PTCA, and subsequently underwent Cypher stent implantation in the total re-occluded target lesion. One and a half years later, the patient died from acute MI and cardiogenic shock due to total re-occlusion of the target lesion. One control patient who had no restenosis at 6 months died of lung carcinoma 64 months after the index procedure. Cumulative repeat PTCA was performed in 3 of 25 (12%) patients with restenosis in the irradiated group and 10 of 25 (40%) in the control group (P=0.051) at the 6-year follow-up. Cumulative TLR was performed in 4 of 25 (16%) patients with restenosis in the irradiated group and 11 of 25 (44%) patients in the control group (P=0.062). Cumulative MACE were significantly different between the irradiated and control groups (5/25 (20%) vs. 14/25 (56%); P=0.019). The cumulative composite clinical endpoints were significantly different between the irradiated and control group (7/25 (28%) vs. 15/25 (60%); P=0.045). The Kaplan -Meier estimates of 6-year survival free from TLR and MACE were log rank P=0.058 and 0.032, respectively (Figures A, B) .
Discussion
Although the pre-procedure reference diameter was significantly larger in the irradiated group, the 2 groups exhibited a similar post-procedure reference diameter. Furthermore, the post-procedure MLD in the control group was significantly larger than that in the irradiation group, and the post-procedure percent of stenosis in the control group was significantly lesser than that in the irradiation group. These differences might be because the IVUS study was performed only to determine vessel size but not for the adequacy of the CBA in the irradiation group. No further intervention was performed using IVUS for unsatisfactory post-CBA results such as small MLD. However, in the control group, an IVUS study was performed to determine the adequacy of the CBA. Published studies on intracoronary brachytherapy for in-stent restenosis have shown that the restenosis rate reduced to 10-30%. [1] [2] [3] [4] [5] [6] [7] [8] [9] Our study demonstrated a remarkable reduction in the restenosis rate, which is similar to that observed in a study conducted by Lee et al; in the latter study, the 6-month restenosis rate was 10% after treatment of diffuse in-stent restenosis with rotational atherectomy and subsequently followed by β-radiation therapy with an 188 Re-MAG3-filled balloon. 8 The good results obtained in our study could probably be attributed to the delivery of the optimal radiation dose over a longer irradiation segment to eliminate a geographic miss and clopidogrel treatment for at least 6 months. Prevention of balloon slipping during cutting balloon inflation might reduce injury length and geographic miss.
Late total occlusion (>30 days after the procedure) in patients undergoing intracoronary brachytherapy has been found to be relatively high, especially in patients who got a new stent for in-stent restenosis. 10-13 Of the 25 patients from the 188 Re irradiation group in our study, 1 (4%) exhibited late total occlusion. Late occlusion occurred in 3 of 25 (12%) patients in the control group. Prolongation of the double antiplatelet regimen in the stent and radiation therapy (START) trial had been shown to achieve a similar rate of late total occlusion in patients administered placebos and brachytherapy. 3 A study conducted by Waksman et al revealed that clopidogrel treatment for 12 months is better than 6 months in reducing overall major cardiac events and revascularization rates at 15 months for patients with in-stent-restenosis treated with β-radiation. 13 No late total occlusion was observed in our study. Therefore, a double antiplatelet regimen is recommended for the treatment of post-intracoronary brachytherapy in-stent restenotic lesions as well as non-irradiated in-stent restenosis.
Analyses of long-term follow-up studies revealed a significant decline in the benefits of intracoronary radiation for in-stent restenosis. [14] [15] [16] [17] [18] The poor long-term outcomes are mainly due to late restenosis and late occlusion. 14- 18 Leon et al reported that in γ-1 trial, the TLR rate increased from 25.2% at 9 months to 47.5% at 5 years after intracoronary brachytherapy using iridium-192 for in-stent restenosis. 17 A study conducted by Iofina et al revealed an increase in TLR rate from 18% at 6 months to 28% at 36 months. 18 Similarly, MACE rate increased from 19% at 6 months to 37% at 36 months. 18 In Iofina's study, 75 mg/day of clopidogrel was administered for 12 months in addition to aspirin. In 2 of the 128 patients, late total occlusion was only observed after 12 months. 18 The angiographic analysis proposed by the Scripps coronary radiation to inhibit proliferation post-stenting trial at the 5-year follow-up, the TLR rate was significantly lower in the iridium-192 group (23.1% vs. 48.3%; P=0.05) than in the placebo group. 15 The 5-year event-free survival was greater in irradiated patients (61.5% vs. 34.5%; P=0.02) than in the placebo group. 15 Our study reports the outcomes for a longest duration of follow-ups of 188 Re irradiated patients with diffuse in-stent restenosis. The late catch-up phenomenon did not occur in our irradiated patients. Cumulative TLR was performed in 16% patients with restenosis in the irradiated group and 44% in the control group (P=0.062). In our study, the increase in TLR rate from 12% at 6 months to 16% in the irradiated patients at 6 years was lower than those
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reported in studies conducted by Leon et al and Iofina et al. 17, 18 Cumulative MACE rates in our study were significantly different between the irradiated and control group (20% vs. 56%; P=0.019). Similarly, composite clinical endpoints were significantly different between the irradiated and control groups (28% vs. 60%; P=0.045). Kim et al conducted a randomized study to evaluate the long-term outcome of intracoronary irradiation using a 188 Re-filled balloon system. 9 In their study, the MACE rate within 3 years was significantly reduced with intracoronary irradiation in the in-stent restenotic subgroup (14.3% vs. 54.5%, P=0.01). 9 Moreover, in the observational study conducted by Lee et al the rate of 30-month cumulative TLR and MACE-free survival were 12% and 86.9±5.0% respectively after treatment of diffuse in-stent restenosis using rotational atherectomy followed by 188 Re irradiation. 8 The favorable long-term angiographic and clinical outcomes in studies of Kim et al, Lee et al and our studies might be attributed to the optimal radiation dosage (14-17.6 Gy at a depth of 1.0 mm into the vessel wall) and the accurate positioning of the source and uniform treatment to the vessel wall provided by intracoronary brachytherapy using a liquid-Re-188-filled balloon catheter. 8,9
Recent randomized trials showed that sirolimus-and paclitaxel-eluting stent implantation is more effective in decreasing restenosis and improving long-term outcomes than intracoronary brachytherapy for diffuse in-stent restenosis. 19, 20 Wohrle et al conducted a non-randomized study comparing intracoronary brachytherapy using liquid 188 Re-filled balloon and paclitaxel-eluting stent for the treatment of in-stent restenosis. 21 The use of paclitaxel-eluting stents was associated with a lower 6-month angiographic total segment restenosis rate (9.1% vs. 23.9%; P=0.08) and MACE rate (4% vs. 15.7%; P<0.05) than 188 Re irradiation. 21 A randomized study that compared sirolimus-eluting stent implantation with liquid 188 Re-filled balloon exhibited a lower 6-month angiographic analysis segment restenosis rate (8% vs. 30.2%; P=0.006), lower TLR rate at 1 year (4.6% vs. 18.8%; P=0.014) and lower MACE rate (7.7% vs. 18.8%; P=0.073). 22 Lee et al conducted a retrospective study to compare 6-month angiographic and 3-year clinical outcomes of 120 consecutive patients with sirolimus-eluting stent implantation in 240 patients who underwent liquid-188 Re-filled balloon irradiation for bare metal diffuse in-stent restenosis. 23 The in-segment angiographic restenosis rates at 6 months were higher in the Re-188 group (26.4% vs. 7.4%; P<0.05) than in the sirolimus-eluting stent group. 23 At 3 years, the MACE free survival rate was higher in the sirolimus-eluting stent group (92.5±2.4% vs. 84.2± 2.4%; P=0.03) than in the 188 Re group. 23 Therefore, the above data supports drug-eluting stent implantation as the treatment of choice for bare-metal in-stent restenosis.
The pattern of in-stent restenosis after drug-eluting stent implantation is mostly focal and could be treated effectively with re-drug-eluting stent placement. 24-27 Re-drug-eluting stent implantation for diffuse drug-eluting stent restenosis was reported to have high re-TLR rate (23-35%). 27-29 However, intracoronary brachytherapy had been shown to achieve a 11% TLR rate and 26% MACE rate in Bonello et al's study, in which 55% of the cases had diffuse or proliferative drug-eluting stent restenosis. 30 Brachytherapy might still be useful in treating diffuse in-stent restenosis following drugeluting stent implantation.
The safety and efficacy of intracoronary brachytherapy using an 188 Re-filled balloon for treating in-stent restenosis have been proven in our study and many other studies too. 5-9,16,21-23 188 Re can be prepared on a daily basis by using a tungsten (W)-188/ 188 Re generator at a relatively low cost. Intracoronary radiation using 188 Re radiation can be performed using a conventional balloon catheter without any additional facilities. Because intracoronary brachytherapy using a 188 Re filled balloon does not require any support from the pharmaceutical or medical devices companies, the sustainability of this type of technology is considerably better than that of other systems.
Study Limitations
This is a single center, non-randomized study with a small sample size. Although clinical data were available in all patients, 3-year angiographic follow-up was incomplete.
Conclusions
Brachytherapy after CBA for diffuse in-stent restenotic native coronary artery using a 188 Re-filled balloon is effective in reducing the target-lesion restenosis rate and improving longterm outcomes.
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